Board of Directors
Board of Directors
Ken Kelley has over 35 years of entrepreneurial, venture capital, operational and technical biotechnology experience. He currently serves on the Board of Directors of Adjuvance Technologies, ID Biologics, Meissa Vaccines, Public Health Vaccines, and publicly held Halozyme Therapeutics. Previously, Mr. Kelley was co-founder, CEO and Chairman of PaxVax. Mr. Kelley was a venture capitalist at K2 BioVentures, Latterell Venture Partners and Institutional Venture Partners (IVP) and has made over 40 biotechnology and medical startup investments. Mr. Kelley was a White House Presidential Executive Fellow from 2016-2017 as well as an Advanced Leadership Initiative (ALI) Fellow at Harvard University from 2015-2016. He earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University.
Dr. Armin Spura
Dr. Armin Spura became a Strategic Advisor and Board Observer to SeromYx in Oct 2021 and was elected to the Board in 2022. Dr. Spura is the CEO of Crown Bioscience, a leading global pre-clinical and translational contract research organization with a particular focus in oncology. Prior to Crown Bioscience Dr. Spura led the Asia Pacific and Greater China expansion strategy for CareDx, a leader in transplant diagnostics, as well as global product commercialization efforts for Wuxi NextCODE’s data analysis and AI solutions. He has also held multiple leadership positions at Life Technologies and Thermo Fisher Scientific, as General Manager for a China-based joint venture with Da’An Diagnostics, as well as GM for Professional Services for the Genomics Business. Earlier in his career, Dr. Spura helped grow two start-up companies: Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Dr. Spura studied Biochemistry in Germany and received his PhD in Molecular Biology from Brown University.
Chief Executive Officer
Piers Whitehead has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health. Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies. As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company’s second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr Whitehead holds a BA with honours from Oxford University.